321 related articles for article (PubMed ID: 23837679)
1. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Mannucci E
Diabetes Obes Metab; 2014 Jan; 16(1):48-56. PubMed ID: 23837679
[TBL] [Abstract][Full Text] [Related]
2. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Martelli D; Mannucci E
Curr Med Res Opin; 2011 Nov; 27 Suppl 3():57-64. PubMed ID: 22106978
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials.
Monami M; Dicembrini I; Mannucci E
Nutr Metab Cardiovasc Dis; 2014 Jul; 24(7):689-97. PubMed ID: 24793580
[TBL] [Abstract][Full Text] [Related]
4. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials.
Dicembrini I; Montereggi C; Nreu B; Mannucci E; Monami M
Diabetes Res Clin Pract; 2020 Jan; 159():107981. PubMed ID: 31870827
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomized controlled trials.
Mannucci E; Nreu B; Montereggi C; Ragghianti B; Gallo M; Giaccari A; Monami M;
Nutr Metab Cardiovasc Dis; 2021 Sep; 31(10):2745-2755. PubMed ID: 34364771
[TBL] [Abstract][Full Text] [Related]
6. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.
Scheen A
Expert Opin Drug Saf; 2013 Jul; 12(4):545-57. PubMed ID: 23621381
[TBL] [Abstract][Full Text] [Related]
7. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
Acta Diabetol; 2020 Jun; 57(6):689-696. PubMed ID: 31955260
[TBL] [Abstract][Full Text] [Related]
8. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Gooßen K; Gräber S
Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
[TBL] [Abstract][Full Text] [Related]
9. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
Silverii GA; Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Wu S; Chai S; Yang J; Cai T; Xu Y; Yang Z; Zhang Y; Ji L; Sun F; Zhan S
Clin Ther; 2017 Sep; 39(9):1780-1789.e33. PubMed ID: 28827024
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
Richard KR; Shelburne JS; Kirk JK
Clin Ther; 2011 Nov; 33(11):1609-29. PubMed ID: 22071236
[TBL] [Abstract][Full Text] [Related]
12. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
[TBL] [Abstract][Full Text] [Related]
14. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
Scheen AJ
Expert Opin Drug Saf; 2015 Apr; 14(4):505-24. PubMed ID: 25630605
[TBL] [Abstract][Full Text] [Related]
15. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Raz I; Bhatt DL; Hirshberg B; Mosenzon O; Scirica BM; Umez-Eronini A; Im K; Stahre C; Buskila A; Iqbal N; Greenberger N; Lerch MM
Diabetes Care; 2014 Sep; 37(9):2435-41. PubMed ID: 24914244
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Safety of Sitagliptin in the TECOS Study.
Buse JB; Bethel MA; Green JB; Stevens SR; Lokhnygina Y; Aschner P; Grado CR; Tankova T; Wainstein J; Josse R; Lachin JM; Engel SS; Patel K; Peterson ED; Holman RR;
Diabetes Care; 2017 Feb; 40(2):164-170. PubMed ID: 27630212
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
[TBL] [Abstract][Full Text] [Related]
18. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
Faillie JL; Babai S; Crépin S; Bres V; Laroche ML; Le Louet H; Petit P; Montastruc JL; Hillaire-Buys D;
Acta Diabetol; 2014; 51(3):491-7. PubMed ID: 24352344
[TBL] [Abstract][Full Text] [Related]
19. Effect of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure: A Network Meta-Analysis.
Guo WQ; Li L; Su Q; Dai WR; Ye ZL
Value Health; 2017 Dec; 20(10):1427-1430. PubMed ID: 29241903
[TBL] [Abstract][Full Text] [Related]
20. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.
Yang W; Cai X; Han X; Ji L
Diabetes Metab Res Rev; 2016 May; 32(4):391-404. PubMed ID: 26417956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
